Closing the cancer divide: Implementing the diagonal approach
Dr Felicia Knaul - Harvard Medical School, Boston, USA
Closing the cancer divide: Implementing the diagonal approach ( Dr Felicia Knaul - Harvard Medical School, Boston, USA )
19 Apr 2013
Utility of robotics in the management of CT detected lung nodules
Giulia Veronesi - European Institute of Oncology, Milan, Italy
Utility of robotics in the management of CT detected lung nodules  ( Giulia Veronesi - European Institute of Oncology, Milan, Italy )
19 Dec 2012
Inequalities in cancer incidence, mortality and survival
Dr Michel Coleman - London School of Hygiene and Topical Medicine, London, UK
Inequalities in cancer incidence, mortality and survival ( Dr Michel Coleman - London School of Hygiene and Topical Medicine, London, UK )
14 Nov 2012
Influence of cachexia on chemotherapy toxicity
Dr Michael Sawyer – University of Alberta, Canada
Influence of cachexia on chemotherapy toxicity ( Dr Michael Sawyer – University of Alberta, Canada )
14 Nov 2012
Patient involvement in improvements in standard of care
Tom Haswell - VNCRI and NCRN Consumer Liaison Groups
Patient involvement in improvements in standard of care ( Tom Haswell - VNCRI and NCRN Consumer Liaison Groups )
14 Nov 2012
Chemotherapy and radiotherapy in advanced local non-small cell lung cancer
Dr Dirk De Ruysscher – University of Leuven, Netherlands
Chemotherapy and radiotherapy in advanced local non-small cell lung cancer ( Dr Dirk De Ruysscher – University of Leuven, Netherlands )
12 Oct 2012
Analysing the efficacy of treatment through Response Evaluation Criteria in Soli...
Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012
MET inhibitors for non-small cell lung cancer
Prof Georgio Scagliotti – University of Torino, Italy
MET inhibitors for non-small cell lung cancer ( Prof Georgio Scagliotti – University of Torino, Italy )
9 Oct 2012
Treatment of ALK+ lung cancer with crizotinib, Profile 1007
Dr Alice Shaw – Massachusetts General Hospital, Boston, USA
Treatment of ALK+ lung cancer with crizotinib, Profile 1007 ( Dr Alice Shaw – Massachusetts General Hospital, Boston, USA )
8 Oct 2012
Phase I study examining PI 3 kinase inhibitor for various tumours
Dr Pamela Munster – University of California, San Francisco, USA
Phase I study examining PI 3 kinase inhibitor for various tumours ( Dr Pamela Munster – University of California, San Francisco, USA )
4 Oct 2012
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-p...
Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )
30 Sep 2012
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib
Dr Tony Mok - Chinese University of Hong Kong
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib ( Dr Tony Mok - Chinese University of Hong Kong )
29 Sep 2012